Recently, GlaxoSmithKline (GSK) announced an agreement with __________ for the early stage research and development of a six-in-one combination paediatric vaccine to help protect children in India and other developing countries from polio and other infectious diseases.
[A]Serum Institute of India
[B]Bharat Biotech Limited
[C]Biological E Limited
[D]Shanta Biotech Limited

Biological E Limited
Multinational drug-maker GlaxoSmithKline and the Hyderabad-based Biological E Limited have come together for early stage research and development of a six-in- one combination paediatric vaccine against polio and other infectious diseases. The vaccine would combine GSK’s injectable polio vaccine (IPV) and Biological E’s pentavalent vaccine for diphtheria, tetanus, whooping cough (whole-cell pertussis), hepatitis B, and Haemophilus influenzae type b. The vaccine would enable fewer injections for children, thereby improving compliance in immunisation schedules. The fully liquid formulation of the vaccine also means it would be ready to use with no additional ingredients or materials required, freeing up space at local storage facilities.